HIMS Stock Options Traders Anticipate Significant Price Volatility Ahead of Earnings Hims & Hers Health (HIMS) stock options traders are signaling a substantial price swing ahead of the company’s upcoming earnings report, with market participants pricing in a potential 14.8% move. As of the latest data, the stock is trading near $26.25, and traders are using the $26 strike price as the at-the-money straddle. The call option for the $26 strike is priced at $2.11, while the put option is at $1.78, resulting in a total cost of $3.89. This pricing suggests a projected post-earnings range of approximately $22.36 to $30.14, reflecting heightened expectations for volatility. Analysts and traders are also observing similar implied moves across nearby strike prices. The $26.50 straddle is priced at $3.87, and the $27 straddle at $4.00, reinforcing the market’s anticipation of a significant price shift. The active positioning around these key strikes indicates that traders are preparing for a sharp reaction, with the $26 call showing 1,391 contracts traded compared to 740 puts. Open interest at the $26 strike is nearly balanced, with 3,167 calls and 3,136 puts outstanding. However, the $26.50 strike leans more bullish, as 3,034 calls have been traded against only 319 puts. The options market’s focus on volatility suggests that investors are bracing for a substantial earnings outcome, rather than a minor price fluctuation. The balanced open interest near the $26 strike implies readiness for a move in either direction, while the heavier call volume at $26.50 points to increased optimism about potential upside.#hims_hers_health #hims #earnings_report #stock_options #wall_street_analysts
Hims & Hers Announces Strategic Shift for US Weight Loss Business Hims & Hers Health, Inc. (NYSE: HIMS) has announced a strategic collaboration with Novo Nordisk to realign its US weight loss offerings with global strategies, focusing on expanding access to FDA-approved GLP-1 medications. The company plans to provide US customers with a broader range of FDA-approved treatments, including compounded semaglutide on a limited scale, while aligning its domestic and international models to position itself as the largest global platform for affordable, approved weight loss medications. The US weight loss market has evolved significantly since Hims & Hers entered the space in 2023. Advances in the industry have led to greater availability of FDA-approved GLP-1 treatments at more affordable prices, with improved dosing flexibility and diverse delivery formats, driving increased demand for branded, regulated medications. As part of this shift, Hims & Hers will discontinue advertising compounded GLP-1 products on its platform or in marketing materials. Existing patients will be transitioned to FDA-approved medications when clinically appropriate, though limited access to compounded GLP-1s will remain available for patients whose needs cannot be met by commercially available options. The partnership with Novo Nordisk will bring Ozempic® (semaglutide) in various dosages, including injectable and pill forms, to the platform later this month. Over time, Hims & Hers will educate customers on their treatment options and support seamless transitions to FDA-approved medications as determined by healthcare providers. The companies aim to expand their collaboration to include additional products as they become available, enhancing the range of treatments available to providers.#semaglutide #hims_hers_health #novo_nordisk #glp_1 #ozempic
